ADAGLeadership•globenewswire•
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
Sentiment:Neutral (40)
Summary
(NASDAQ:ADAG) SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 3, 2025 by globenewswire